Emerging Treatment Options for Myelodysplastic Syndromes

 

Related Videos (117)

James K. Mangan, MD, PhD, describes the management of the myelodysplastic syndromes, a diverse group of clonal hematopoietic stem or progenitor cell disorders, as represented by clinical trials presented at ASH 2015 and currrent enrolling clinical trials at Penn Medicine. Dr. Mangan provides algorithms for the treatment of primary, intermediate and high-risk MDS and their respective prognoses as determined by somatic mutations, as well as current and evolving therapies at each level of severity.

 

Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®